Get started
Author

Stefanie Mullins

Observed names: Mullins, Stefanie, S. Mullins, Stef Mullins, Stefanie R Mullins, Stefanie R. Mullins, Stefanie Roshy Mullins
Observed institutions: AstraZeneca (United Kingdom), Fox Chase Cancer Center, 3M (United States), University of Toronto, Wayne State University, The Barbara Ann Karmanos Cancer Institute, F-star (United Kingdom), University of Pennsylvania
ORCID: 0000-0003-4433-2288
Observed ORCID: 0000-0003-4433-2288
OpenAlex ID: A5034405695
Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
2016 · Suzanne I.S. Mosely, John E. Prime, et al. · Cancer Immunology Research · 422
Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody
2015 · Ross Stewart, Michelle Morrow, et al. · Cancer Immunology Research · 413
Dynamic imaging of protease activity with fluorescently quenched activity-based probes
2005 · Galia Blum, Stefanie R Mullins, et al. · Nature Chemical Biology · 360
FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells
2011 · Hyung-Ok Lee, Stefanie R Mullins, et al. · BMC Cancer · 323
PDF
Phase II trial of single agent Val-boroPro (talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer
2007 · Kalyani Narra, Stefanie R. Mullins, et al. · Cancer Biology & Therapy · 285
PDF
Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
2019 · Stefanie R. Mullins, John P. Vasilakos, et al. · Journal for ImmunoTherapy of Cancer · 187
PDF
Photodynamic Molecular Beacon Triggered by Fibroblast Activation Protein on Cancer-Associated Fibroblasts for Diagnosis and Treatment of Epithelial Cancers
2008 · Pui-Chi Lo, Juan Chen, et al. · Journal of Medicinal Chemistry · 108
Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model
2016 · Nadia M. Luheshi, Jane Coates-Ulrichsen, et al. · Oncotarget · 100
PDF
p21-Activated Kinase 1 Coordinates Aberrant Cell Survival and Pericellular Proteolysis in a Three-Dimensional Culture Model for Premalignant Progression of Human Breast Cancer
2008 · Quanwen Li, Stefanie Roshy Mullins, et al. · Neoplasia · 87
PDF
The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
2017 · Edmund Poon, Stefanie Mullins, et al. · Journal for ImmunoTherapy of Cancer · 76
PDF
A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist
2017 · Rebecca Leyland, Amanda Watkins, et al. · Clinical Cancer Research · 52
Imaging and quantifying the dynamics of tumor-associated proteolysis
2008 · Mansoureh Sameni, Dora Cavallo-Medved, et al. · Clinical & Experimental Metastasis · 49
Intratumoral administration of the Toll‐like receptor 7/8 agonist 3M‐052 enhances interferon‐driven tumor immunogenicity and suppresses metastatic spread in preclinical triple‐negative breast cancer
2020 · Damien J Zanker, Alex J Spurling, et al. · Clinical & Translational Immunology · 35
PDF
Optoacoustic Detection of Early Therapy-Induced Tumor Cell Death Using a Targeted Imaging Agent
2017 · Bangwen Xie, Michal R. Tomaszewski, et al. · Clinical Cancer Research · 33
PDF
Three-dimensional cultures modeling premalignant progression of human breast epithelial cells: role of cysteine cathepsins
2012 · Stefanie R. Mullins, Mansoureh Sameni, et al. · Biological Chemistry · 30
Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens
2012 · Jiping Zhang, Matthildi Valianou, et al. · The FASEB Journal · 22
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
2016 · Casey Ager, Matthew Reilley, et al. · Journal for ImmunoTherapy of Cancer · 17
PDF
Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models
2024 · Brajesh P. Kaistha, Gozde Kar, et al. · Cancer Biology & Therapy · 10
Preclinical modelling of immune checkpoint blockade (P2012)
2013 · Ross Stewart, Stefanie Mullins, et al. · The Journal of Immunology · 6
Abstract 4697: Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment and holds potential for combination with immune checkpoint inhibitors
2017 · Stefanie R. Mullins, Katharina Vogel, et al. · Cancer Research · 2
Microarrays for Protease Detection in Tissues and Cells
2009 · Kamiar Moin, Donald Schwartz, et al. · Methods in molecular biology · 2
Abstract 1584: Efficacy and pharmacodynamic effect of anti-CD73/PD-L1 monoclonal antibodies in combination with chemotherapy: Observations from mouse tumor models
2021 · Jim Eyles, Amanda Watkins, et al. · Cancer Research · 1
Abstract 711: Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
2018 · Stefanie R. Mullins, John Vasilakos, et al. · Cancer Research · 1
Abstract 1475: Local immune activation resulting in tumor growth inhibition with MEDI9197 - an intratumorally administered TLR7/8 agonist
2016 · Stefanie Mullins, Iwen Grigsby, et al. · Cancer Research · 1
Immune mediated therapy and MEK inhibition: preclinical assessment of immunobiology and combination activity in vitro and in vivo
2014 · Ross Stewart, Edmund Poon, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Works count: 50
Citation count: 2,624
H-index: 17
I10-index: 18
Year
Topic
Type